Francis Worden

7PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Dec 12, 2025
FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.

Michelle Mierzwa, Benjamin Rosen, Krithika Suresh

|Jun 26, 2024
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.

Jena D French, Bryan R Haugen, Francis P Worden

|Mar 22, 2024
Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC.

Paul L Swiecicki, Emily Bellile, Aleksandar F Dragovic

|Dec 15, 2023
Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.

Francis Worden, Olivera Rajkovic-Hooley, Neil Reynolds

|Aug 29, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar

|Oct 04, 2022
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.

Cherie-Ann O Nathan, D Neil Hayes, Theodore Karrison

Pageof 2

Frequent Collaborators

3 joint publications

Michelle Mierzwa

3 joint publications

Chaz Stucken

3 joint publications

Mark Prince

3 joint publications

Jennifer Shah